RoboSense Launched E1, A High-Performance Flash Solid-State LiDAR and Debuted A Smart Manufacturing System with An Annual Output of A Million Units
8.11.2022 15:28:00 EET | Business Wire | Press release
RoboSense, a world-leading provider of Smart LiDAR Sensor Systems, held a new product launch and Tech Day event. During the conference, RoboSense officially launched RS-LiDAR-E1 (E1), a flash solid-state LiDAR that sees 360° based on its in-house, custom developed chips and flash technology platform. Also debuted was the only China National Accreditation Service (CNAS) recognized on-board LiDAR lab of the industry to date, and held the unveiling ceremony of the smart manufacturing joint venture, Luxsense, jointly with Luxshare-ICT, a domestic leading electronics manufacturer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221108005666/en/
RoboSense Tech Day Launched E1, A High-Performance Flash Solid-State LiDAR and Debuted A Smart Manufacturing System with An Annual Output of A Million Units (Graphic: Business Wire)
RoboSense launched E1, the first automotive-grade flash solid-state LiDAR. It serves as a new product platform featuring area array transceiver technology with application-specific developed chips as the core. E1 is designed for large-scale series production with a simple bill of materials including no moving parts, and excels in all the three aspects of detection performance, cost efficiency and automotive-grade safety and reliability of LiDARs. As a key piece to realizing the core functions of autonomous driving, E1 will assist partners to further bridge the gap in smart driving perception and improve the all-scenario perception capability of automated and autonomous vehicles.
4 core features of E1
- Horizontal FOV of 120°, which ensures 360° coverage area without blind zone using minimum sensors.
- Vertical FOV is designed to be 90°, to allow the perception area to cover both blind zones on the ground and lateral vision.
- Ultra-high frame rates of over 25Hz, capturing target objects’ motion states and predicting their moves faster.
- Detection range of 30m @10%, which enables better perception planning control.
E1 uses RoboSense’s first in-house, custom chips for flash solid-state LiDAR platform and its first 2D electronic scanning technology. With highly integrated chips that incorporate the three core components of transmission, reception, and processing, E1 greatly streamlines the circuit design and production processes, creating the performance and cost advantages necessary for the durability and reliability requirements of blind spot LiDARs in the automotive market.
To ensure product performance and rapidly improve production capacity, RoboSense launched the first and only CNAS certified LiDAR lab to analyze LiDAR and their components and developed a complementary smart manufacturing system to produce this high-tech, precision sensor.
During the event, leaders of RoboSense and Luxshare jointly held the unveiling ceremony of Luxsense. Investment in the first phase of RoboSense smart manufacturing system exceeded 1 billion RMB cumulatively; the plant area exceeds 55,000 square meters including nearly 20 automated production lines built with highly intelligent production software to achieve a top-level production efficiency of “a LiDAR every 12 seconds” and guarantees capacity by connecting our Shenzhen, Dongguan and Guangzhou plants.
Additionally, RoboSense announced a new strategic financing round which attracted top industry investors. In particular, industry investors in this new financing round include car companies with self-owned brands, emerging automakers, top luxury supercar brands, leading commercial vehicle companies, supply chain pioneers and the tier 1 institutions. Greatly empowered by capital investments from the industry, RoboSense gained unprecedented momentum and sustainability.
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. With a complete portfolio of LiDAR sensors, AI perception and IC chipsets, RoboSense transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221108005666/en/
Contact information
Grace Ye
media@robosense.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom